Amblyopia can be produced in rhesus monkeys by suturing the lids of one eye (visual deprivation amblyopia) or by producing artificial esotropia (strabismic amblyopia) during visual immaturity. Sections from retinas, lateral geniculate nuclei (LGN), and areas 17 and 18 of the visual cortex from ...
1.Kohei Shitara, et al.Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer. LBA3, ES...
[3]Alva, A., et al. LBA23 - Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361. Ann Oncol, 2020. 31: S1142. [4]Powles, T., et al. Durvalumab alone and durvalumab plus tremelimumab versus che...
英英 网络释义 n. 1. 气相色谱法 2. 气体色谱法 3. 千兆周 例句 释义: 全部,气相色谱法,气体色谱法,千兆周 更多例句筛选 1. Weeklylow-dose MTXisaneffectivemeansofinducingremissionandminimizingGCtherapyandtoxicityinmostofthesepatients. 对于这些患者中的大多数而言,每周用低剂量的MTX是一个诱导缓解和减小GC...
1. K. Shitara, S.Y. Rha, L.S. Wyrwicz, et al. Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-...
The pathogenesis of AD is still unclear, and the recognized causes include acetylcholine deficiency, free radicals, and inflammation of brain tissue; and there is no cure, but effective drug therapy can improve the patients’ symptoms to improve the quality of life [6–8]. Many medicines in ...
One of the ways to improve and expand the fields of application of radiation and photodynamic therapy of cancer is the use ... AB Vlasenko,VV Bakhmetyev,NA Khristyuk - 《Journal of Physics Conference》 被引量: 0发表: 2020年 加载更多...
The primary objective of this study was to determine the objective response rate of DJ-927 as 2nd-line therapy in pts with advanced GC. Eligible pts had confirmed advanced GC with no more than 1 prior systemic 5-FU-containing regimen for advanced disease, with adequate hematologic, renal and...
1.Juncell Therapeutics Announces Clinical Data of GC203 TIL therapy in Ovarian Cancer at ASCO 2024 (prnewswire.com) 2.A phase I single-arm, open-label trial of engineering tumor-infiltrating lymphocytes with membrane-bound IL-7 for recurrent ovarian cancer. | Journal of Clinical Oncology (asco...
[3]Pedersen M,et al.Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. Oncoimmunology. 2018 Sep 26;7(12):e1502905. doi: 10.1080/2162402X.2018.1502905. PMID: 30524900; PMCID: PMC6279323. ...